HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A unified approach to risk assessment for fetal aneuploidies.

AbstractOBJECTIVE:
To examine the potential impact of combining measures from cell-free DNA (cfDNA) testing with maternal age and first-trimester biomarkers in screening for fetal trisomies.
METHODS:
This was a theoretical study using Bayes' theorem to combine the a priori risk for fetal trisomy 21 derived from maternal age with likelihoods from nuchal translucency thickness, serum pregnancy-associated plasma protein-A, serum free β-human chorionic gonadotropin and plasma cfDNA. We adopted a binomial counting model for the cfDNA likelihoods and developed a model to account for errors in estimating fetal fraction.
RESULTS:
When Bayes' theorem was used to combine the a priori risk for trisomy 21 derived from the first-trimester combined test with likelihoods from the cfDNA test, and when the true fetal fraction was known, the detection rate increased from 62% at a fetal fraction of 4% to 100% at a fetal fraction of ≥ 9%; the positive likelihood ratio (trisomic/euploid) increased from 620 to 1000 and the negative likelihood ratio (euploid/trisomic) increased from 3 to > 10 000. When the fetal fraction is < 4%, the cfDNA test has traditionally been considered to be a failure, but the cfDNA results can be used to improve the performance of screening by the combined test.
CONCLUSIONS:
In contingent policies that use the first-trimester combined test for first-line screening to select the subgroup for cfDNA testing, the data from the latter should be used to update the risk from the former. Individual patient results from cfDNA testing depend crucially on the fetal fraction and the precision of its measurement.
AuthorsD Wright, A Wright, K H Nicolaides
JournalUltrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology (Ultrasound Obstet Gynecol) Vol. 45 Issue 1 Pg. 48-54 (Jan 2015) ISSN: 1469-0705 [Electronic] England
PMID25315809 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2014 ISUOG. Published by John Wiley & Sons Ltd.
Chemical References
  • Biomarkers
  • Chorionic Gonadotropin, beta Subunit, Human
  • DNA
  • Pregnancy-Associated Plasma Protein-A
Topics
  • Bayes Theorem
  • Biomarkers (blood)
  • Cell-Free System
  • Chorionic Gonadotropin, beta Subunit, Human (blood)
  • DNA (genetics)
  • Down Syndrome (blood, diagnosis, genetics)
  • Female
  • Humans
  • Maternal Age
  • Maternal Serum Screening Tests
  • Nuchal Translucency Measurement
  • Pregnancy
  • Pregnancy Trimester, First (blood)
  • Pregnancy-Associated Plasma Protein-A (metabolism)
  • Prenatal Diagnosis
  • Risk Assessment

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: